ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
상피종 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 9.8%의 연평균 성장률로 76억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 표적 치료제 사용 확대, 면역치료 연구 발전, 최소침습적 치료 선호도 증가, 신흥 지역 전반의 의료 인프라 개선, 새로운 상피종 치료에 대한 규제 당국의 승인에 의해 이루어질 것으로 예상됩니다. 이 기간 동안 예상되는 주요 동향으로는 맞춤형 의료의 발전, 피부암 진단에 AI 도입, 병용요법의 적용 확대, 새로운 치료법의 임상시험 증가, 비침습적 치료법으로의 전환 증가 등이 있습니다.
피부암 발병률의 증가는 상피종 치료 시장의 성장을 촉진할 것으로 예상됩니다. 피부암은 비정상적인 피부세포의 통제할 수 없는 증식을 동반하며, 그 전형적인 원인은 복구되지 않는 DNA 손상으로 인한 돌연변이입니다. 피부암 환자 증가의 주요 요인은 오존층 파괴와 같은 환경 문제와 함께 햇빛과 선탠베드로 인한 자외선 노출의 증가입니다. 상피종 치료는 암화된 상피세포를 제거하는 것을 목표로 하며, 피부암의 근본적인 원인을 효과적으로 표적으로 삼고 있습니다. 예를 들어, 2024년 1월 미국암협회는 2024년 미국에서 예상되는 신규 흑색종 환자 수는 약 10,640명(남성 약 5만 9,170명, 여성 약 4만 1,470명)으로 추정된다고 보고했습니다. 이러한 환자 수의 증가는 상피종 치료 시장 확대를 촉진하는 중요한 요인으로 작용하고 있습니다.
상피종 치료 시장의 주요 업체들은 치료 정확도 향상, 환자 예후 개선, 맞춤형 의료 전략 지원을 위해 동반진단제와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 동반진단제는 안전성과 치료 효과를 극대화하고 특정 치료의 혜택을 가장 많이 받을 가능성이 가장 높은 환자를 식별하기 위해 고안된 특수 검사입니다. 예를 들어, 2024년 11월 스위스에 본사를 둔 제약회사 Roche Holdings AG는 PATHWAY 항-HER2/neu(4B5) 토끼 단일클론 1차 항체 검사에 대한 FDA의 용도 확대 승인을 받았습니다. 이번 승인으로 디헬라(성분명: 자니다타맙-hrii)로 치료받을 수 있는 치료 경험이 있는 절제불능 또는 전이성 HER2 양성 담도암(BTC) 환자를 선별할 수 있게 됐습니다. 로슈의 목표는 BTC에서 표적 치료 결정을 안내하는 신뢰할 수 있는 진단 도구를 제공함으로써 맞춤형 의료를 촉진하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 상피종 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 상피종 치료 시장 : 성장률 분석
세계의 상피종 치료 시장 실적 : 규모와 성장, 2019-2024년
세계의 상피종 치료 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계 상피종 치료 전체 시장(TAM)
제6장 시장 세분화
세계의 상피종 치료 시장 : 질환 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
기저세포 상피종
편평 상피종
악성 상피종
세계의 상피종 치료 시장 : 치료 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
약물 클래스
외과적 치료
방사선 치료
광역학 요법
병용요법
세계의 상피종 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
E-Commerce
기타 유통 채널
세계의 상피종 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
전문 클리닉
외래 수술 센터
조사·학술기관
세계의 상피종 치료 시장 : 기저세포 상피종 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
표재성 기저세포 상피종
결절성 기저세포 상피종
침윤성 기저세포 상피종
경화성 기저세포 상피종
색소성 기저세포 상피종
세계의 상피종 치료 시장 : 편평 상피종 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
피부 편평상피암
구강 편평상피암
식도 편평상피암
폐 편평상피암
자궁 경부 편평상피암
세계의 상피종 치료 시장 : 악성 상피종 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
상피세포 육종
투명세포 육종
방추세포 암
선양낭성 암
점액표피 암
제7장 지역별·국가별 분석
세계의 상피종 치료 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 상피종 치료 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
상피종 치료 시장 : 경쟁 구도
상피종 치료 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Novartis AG
Eli Lilly and Company
Amgen Inc.
Regeneron Pharmaceuticals Inc.
Sun Pharmaceutical Industries Ltd.
Zhejiang Hisun Pharmaceutical Co. Ltd.
Verrica Pharmaceuticals Inc.
Sirnaomics Inc.
MediWound Ltd
Philogen SpA
PellePharm, Inc.
Kintor Pharmaceutical Limited
DermBiont
Transgene SA
AiViva BioPharma Inc
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
상피종 치료 시장 2029 : 새로운 기회를 제공하는 국가
상피종 치료 시장 2029 : 새로운 기회를 제공하는 부문
상피종 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Epithelioma treatment refers to medical interventions aimed at managing epithelioma, a tumor that develops from epithelial cells covering various surfaces and organs of the body. Treatment options include tumor removal through surgery, radiation therapy to target malignant cells, and chemotherapy for more advanced or widespread cases. The choice of treatment depends on the tumor's type, stage, and location, as well as the patient's overall health and preferences.
The primary types of epithelioma requiring treatment are basal cell epithelioma, squamous cell epithelioma, and malignant epithelioma. Basal cell epithelioma is a slow-growing tumor of the skin that originates from the basal cells in the epidermis. Treatment methods for this condition include drug therapies, surgery, radiation therapy, photodynamic therapy, and combination treatments. These therapies are distributed through hospital pharmacies, retail pharmacies, e-commerce platforms, and other channels. The treatments are most commonly used in hospitals, specialty clinics, ambulatory surgical centers, and academic or research institutions.
The epithelioma treatment market research report is one of a series of new reports from The Business Research Company that provides epithelioma treatment market statistics, including the epithelioma treatment industry global market size, regional shares, competitors with the epithelioma treatment market share, detailed epithelioma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the epithelioma treatment industry. This epithelioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The epithelioma treatment market size has grown rapidly in recent years. It will grow from $4.76 billion in 2024 to $5.24 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth observed during the historic period can be attributed to the rising number of epithelioma cases, progress in radiation therapy, increased reliance on surgical procedures, heightened awareness of skin cancer, and the development of chemotherapy treatments.
The epithelioma treatment market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period is driven by the expanding use of targeted therapies, advancements in immunotherapy research, increasing preference for minimally invasive procedures, improvements in healthcare infrastructure across emerging regions, and regulatory approvals for new epithelioma medications. Key trends expected in this period include the advancement of personalized medicine, adoption of AI in skin cancer diagnostics, growing application of combination therapies, a rise in clinical trials for novel treatment methods, and an increasing shift toward non-invasive treatment options.
The increasing incidence of skin cancers is expected to drive the growth of the epithelioma treatment market. Skin cancer involves the uncontrolled growth of abnormal skin cells, typically resulting from unrepaired DNA damage that causes mutations. A major contributing factor to the rise in skin cancer cases is increased exposure to ultraviolet radiation from sunlight and tanning beds, along with environmental issues such as ozone layer depletion. Epithelioma treatments aim to eliminate cancerous epithelial cells, effectively targeting the underlying cause of skin cancer. For example, in January 2024, the American Cancer Society reported an estimated 100,640 new melanoma cases projected in the U.S. for 2024, with about 59,170 in men and 41,470 in women. This growing number of cases is a key factor fueling the expansion of the epithelioma treatment market.
Leading companies in the epithelioma treatment market are prioritizing the development of innovative therapies, such as companion diagnostics, to improve treatment accuracy, enhance patient outcomes, and support personalized medicine strategies. Companion diagnostics are specialized tests designed to identify patients who are most likely to benefit from specific treatments, maximizing safety and therapeutic effectiveness. For instance, in November 2024, Roche Holdings AG, a pharmaceutical company based in Switzerland, received FDA approval for an expanded use of its PATHWAY anti-HER2/neu (4B5) rabbit monoclonal primary antibody test. This approval enables the test to identify patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with Ziihera (zanidatamab-hrii). Roche's goal is to advance personalized healthcare by offering a reliable diagnostic tool to guide targeted therapy decisions in BTC.
In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, acquired Epizyme Inc. to expand its oncology portfolio. This acquisition grants Ipsen access to Epizyme's innovative cancer treatments, including its lead EZH2 inhibitor, Tazverik. Epizyme Inc. is a U.S.-based biopharmaceutical firm specializing in epithelioma treatment.
Major players in the epithelioma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Verrica Pharmaceuticals Inc., Sirnaomics Inc., MediWound Ltd, Philogen SpA, PellePharm, Inc., Kintor Pharmaceutical Limited, DermBiont, Transgene SA, AiViva BioPharma Inc.
North America was the largest region in the epithelioma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epithelioma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the epithelioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epithelioma treatment market consists of revenues earned by entities providing services such as radiation therapy, chemotherapy, and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelioma treatment market also includes sales of pharmaceuticals, immunotherapy drugs, and advanced treatment modalities designed to improve patient outcomes and reduce the risk of recurrence or metastasis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Epithelioma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on epithelioma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for epithelioma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epithelioma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Epithelioma Treatment Market Characteristics
3. Epithelioma Treatment Market Trends And Strategies
4. Epithelioma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Epithelioma Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Epithelioma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Epithelioma Treatment Market Growth Rate Analysis
5.4. Global Epithelioma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Epithelioma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Epithelioma Treatment Total Addressable Market (TAM)
6. Epithelioma Treatment Market Segmentation
6.1. Global Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Basal Cell Epithelioma
Squamous Cell Epithelioma
Malignant Epithelioma
6.2. Global Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drug Class
Surgical Treatments
Radiation Therapy
Photodynamic Therapy
Combination Therapies
6.3. Global Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Other Distribution Channels
6.4. Global Epithelioma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Research And Academic Institutes
6.5. Global Epithelioma Treatment Market, Sub-Segmentation Of Basal Cell Epithelioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Superficial Basal Cell Epithelioma
Nodular Basal Cell Epithelioma
Infiltrative Basal Cell Epithelioma
Morpheaform (Sclerosing) Basal Cell Epithelioma
Pigmented Basal Cell Epithelioma
6.6. Global Epithelioma Treatment Market, Sub-Segmentation Of Squamous Cell Epithelioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cutaneous Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Pulmonary Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
6.7. Global Epithelioma Treatment Market, Sub-Segmentation Of Malignant Epithelioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epithelioid Sarcoma
Clear Cell Sarcoma
Spindle Cell Carcinoma
Adenoid Cystic Carcinoma
Mucoepidermoid Carcinoma
7. Epithelioma Treatment Market Regional And Country Analysis
7.1. Global Epithelioma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Epithelioma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Epithelioma Treatment Market
9.1. China Epithelioma Treatment Market Overview
9.2. China Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Epithelioma Treatment Market
10.1. India Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Epithelioma Treatment Market
11.1. Japan Epithelioma Treatment Market Overview
11.2. Japan Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Epithelioma Treatment Market
12.1. Australia Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Epithelioma Treatment Market
13.1. Indonesia Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Epithelioma Treatment Market
14.1. South Korea Epithelioma Treatment Market Overview
14.2. South Korea Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Epithelioma Treatment Market
15.1. Western Europe Epithelioma Treatment Market Overview
15.2. Western Europe Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Epithelioma Treatment Market
16.1. UK Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Epithelioma Treatment Market
17.1. Germany Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Epithelioma Treatment Market
18.1. France Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Epithelioma Treatment Market
19.1. Italy Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Epithelioma Treatment Market
20.1. Spain Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Epithelioma Treatment Market
21.1. Eastern Europe Epithelioma Treatment Market Overview
21.2. Eastern Europe Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Epithelioma Treatment Market
22.1. Russia Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Epithelioma Treatment Market
23.1. North America Epithelioma Treatment Market Overview
23.2. North America Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Epithelioma Treatment Market
24.1. USA Epithelioma Treatment Market Overview
24.2. USA Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
